FATE THERAPEUTICS INC FATE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-13.3
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6.6M | -$136.3M | — | -$112.0M | $207.2M |
| 2024 | $13.6M | -$186.3M | — | -$123.6M | $318.7M |
| 2023 | $63.5M | -$160.9M | — | -$138.4M | $368.4M |
| 2022 | $96.3M | -$281.7M | — | -$283.8M | $483.9M |
| 2021 | $55.8M | -$212.2M | — | -$213.6M | $678.8M |
| 2020 | $31.4M | -$173.4M | — | -$44.2M | $384.4M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.3 (distress)
- Working capital / assets 0.541
- Retained earnings / assets -4.811
- EBIT / assets -0.463
- Equity / liabilities 1.854
Source: SEC EDGAR filings · CIK 0001434316 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.